InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
5,471.05
(
1.16%
)
US TECH 100
18,206.40
(
1.44%
)
Dow Jones
40,829.59
(
1.20%
)
Brent Oil
71.72
(
0.25%
)
Bitcoin
57,418.79
(
4.65%
)
Post# of 253074
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Keep Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 838
Posts 120399
Boards Moderated 18
Alias Born 09/05/2002

DewDiligence

Member Level

Re: DewDiligence post# 71694

Thursday, 01/28/2010 7:45:28 AM

Thursday, January 28, 2010 7:45:28 AM

Post# of 253074
Teva has challenged the four Viread patents in the Orange Book, all of which expire in Jul 2017 (and could be extended to Jan 2018 with a pediatric extension):

http://finance.yahoo.com/news/Gilead-Sciences-Announces-bw-109892380.html?x=0&.v=1

I consider this new challenge a long shot and tangential to Teva’s main goal of being the first to market with 180 days of exclusivity for generic Truvada no later than Jan 2018. To accomplish this, Teva will have to knock out the two Emtriva patents that run until 2021, but I think they can, as explained in #msg-34894135.


“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Keep Last Read Next 10 Report Keyboard Shortcuts
Next 10 Prev Next
Join InvestorsHub

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up